Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Adverse events following 9-valent human papillomavirus vaccine (9vHPV) reported to the Vaccine Adverse Event Reporting System (VAERS)
Filetype[PDF-522.88 KB]


Details:
  • Supporting Files:
    No Additional Files
    1. Rapid cycle analysis of the 9-valent human papillomavirus vaccine (9vHPV) in the Vaccine Safety Datalink
      Personal Author:
      Donahue, James; Kieke, Burney A.; McClure, David; Hanson, Kayla; Belongia, Edward A;
      Corporate Authors:
      Marshfield Clinic Research Institute.. Vaccine Safety Datalink.
      Conference Authors:
      United States. Advisory Committee on Immunization Practices. Meeting (2018 February 21-22 : Atlanta, GA)
      Published Date:
      4/19/18
      Series:
      ACIP meeting Human Papillomavirus (HPV) Vaccines Update
      Description:
      Presentations February 2018 Day 1Publication date from document properties.HPV-03-Donahue-508.pdf
      File Type:
      Filetype[PDF - 409.90 KB]
    2. Trends in HPV-associated cancers — United States, 1999–2014
      Personal Author:
      Van Dyne, Elizabeth A.
      Corporate Authors:
      National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division of Cancer Prevention and Control. Epidemiology and Applied Research Branch.
      Conference Authors:
      United States. Advisory Committee on Immunization Practices. Meeting (2018 February 21-22 : Atlanta, GA)
      Published Date:
      9/5/18
      Series:
      ACIP meeting Human Papillomavirus (HPV) Vaccines Update
      Description:
      Presentations February 2018 Day 1Publication date from document properties.HPV-05-Van-Dyne-508.pdf
      File Type:
      Filetype[PDF - 693.08 KB]
    3. Epidemiology of HPV infection in male
      Personal Author:
      Chaturvedi, Anil K.
      Corporate Authors:
      National Cancer Instittue (U.S.)
      Conference Authors:
      United States. Advisory Committee on Immunization Practices. Meeting (2018 February 21-22 : Atlanta, GA)
      Published Date:
      3/7/18
      Series:
      ACIP meeting Human Papillomavirus (HPV) Vaccines Update
      Description:
      Presentations February 2018 Day 1Publication date from document properties.HPV-06-Chaturvedi-508.pdf
      File Type:
      Filetype[PDF - 892.74 KB]
    4. Harmonization of HPV vaccination age recommendations for females and males : background and considerations
      Personal Author:
      Markowitz, Lauri E.
      Corporate Authors:
      National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
      Conference Authors:
      United States. Advisory Committee on Immunization Practices. Meeting (2018 February 21-22 : Atlanta, GA)
      Published Date:
      3/6/18
      Series:
      ACIP meeting Human Papillomavirus (HPV) Vaccines Update
      Description:
      Presentations February 2018 Day 1Publication date from document properties.HPV-04-Markowitz-508.pdf
      File Type:
      Filetype[PDF - 636.23 KB]
    5. Human Papillomavirus Vaccines Session
      Personal Author:
      Szilagyi, Peter
      Corporate Authors:
      United States. Advisory Committee on Immunization Practices. HPV Vaccines Work Group.
      Conference Authors:
      United States. Advisory Committee on Immunization Practices. Meeting (2018 February 21-22 : Atlanta, GA)
      Published Date:
      3/6/18
      Series:
      ACIP meeting Human Papillomavirus (HPV) Vaccines Update
      Description:
      Presentations February 2018 Day 1Publication date from document properties.HPV-01-Szilagyi-508.pdf
      File Type:
      Filetype[PDF - 138.65 KB]
You May Also Like:
  1. Assessing the safety of 9-valent human papillomavirus vaccine administration among pregnant women: adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014–2017
    Personal Author:
    Landazabal, Claudia S.; Moro, Pedro L.; Lewis, Paige; Omer, Saad B.;
    Published Date:
    January 16 2019
    Source:
    Vaccine. 37(9):1229-1234
    Description:
    Introduction9-valent human papillomavirus vaccine (9vHPV) was approved by the Food and Drug Administration (FDA) in December 2014. 9vHPV is not recommended during pregnancy but it is possible that some women of childbearing age might be inadvertently...
    File Type:
    Filetype[PDF - 773.06 KB]
  2. Coming Soon
    Safety of the 9-Valent Human Papillomavirus Vaccine
    Personal Author:
    Shimabukuro, Tom T.; Su, John R.; Marquez, Paige L.; Mba-Jonas, Adamma; Arana, Jorge E.; Cano, Maria V.;
    Published Date:
    November 18 2019
    Source:
    Pediatrics. 144(6)
    Description:
    BACKGROUND:The 9-valent human papillomavirus vaccine (9vHPV) was approved for females and males aged 9 to 26 years in 2014. We analyzed postlicensure surveillance reports to the Vaccine Adverse Event Reporting System (VAERS).METHODS:We searched VAERS...
    Public Access
    Available on:
    December 01, 2020
  3. 2463. Post-licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014–2017
    Personal Author:
    Arana, Jorge; Su, John; Lewis, Paige; Cano, Maria; Markowitz, Lauri E; Shimabukuro, Tom;
    Conference Authors:
    IDWeek (2018 October 3-7 : San Franciso, CA)
    Published Date:
    Nov 26 2018
    Source:
    Open Forum Infect Dis. 2018; 5(Suppl 1):S738.
    Description:
    Background9-valent human papillomavirus vaccine (9vHPV) was licensed in December 2014 and recommended by the Advisory Committee on Immunization Practices (ACIP) in February 2015. 9vHPV is FDA-approved for females and males aged 9–26 years; ACIP rec...
    File Type:
    Filetype[PDF - 59.88 KB]
  4. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
    Personal Author:
    Gee, Julianne; Weinbaum, Cindy; Sukumaran, Lakshmi; Markowitz, Lauri E.;
    Published Date:
    Mar 30 2016
    Source:
    Hum Vaccin Immunother. 2016; 12(6):1406-1417.
    Description:
    Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United States in 2006 and through 2015 was the predominate HPV vaccine used. With the exception of syncope, a known preventable adverse event after any injected vaccination...
    File Type:
    Filetype[PDF - 446.81 KB]
  5. Rapid cycle analysis of the 9-valent human papillomavirus vaccine (9vHPV) in the Vaccine Safety Datalink
    Personal Author:
    Donahue, James; Kieke, Burney A.; McClure, David; Hanson, Kayla; Belongia, Edward A;
    Corporate Authors:
    Marshfield Clinic Research Institute.. Vaccine Safety Datalink.
    Conference Authors:
    United States. Advisory Committee on Immunization Practices. Meeting (2018 February 21-22 : Atlanta, GA)
    Published Date:
    4/19/18
    Series:
    ACIP meeting Human Papillomavirus (HPV) Vaccines Update
    Description:
    Presentations February 2018 Day 1Publication date from document properties.HPV-03-Donahue-508.pdf
    File Type:
    Filetype[PDF - 409.90 KB]